Abstract
Src family kinases are involved in the regulation of a wide variety of normal cellular signal transduction pathways, such as cell growth, differentiation, survival, adhesion and migration. Considerable evidence implicates elevated expression and/or activity of Src kinases in many human cancers, osteoporosis, cardiovascular disorders and immune system dysfunction; thus, this family of protein tyrosine kinases now exists as intriguing targets for both basic research and drug discovery. Herein, a number of examples of currently developed Src family kinase inhibitors in selected patents from 2002 - 2005 will be described. Special attention will be made to the chemical diversity of ATP binding site inhibitors, potency, selectivity and therapeutic application of the compounds.
Original language | English (US) |
---|---|
Pages (from-to) | 1183-1207 |
Number of pages | 25 |
Journal | Expert Opinion on Therapeutic Patents |
Volume | 15 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2005 |
Externally published | Yes |
Keywords
- Cancer
- Drug discovery
- Inhibitor
- Myocardial infarction
- Osteoporosis
- Protein kinase
- SH2 domain
- Src
- Src family kinase
- Tyrosine kinase
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Pharmacology
- Law